Hypertension (High Blood Pressure News and Research RSS Feed - Hypertension (High Blood Pressure News and Research

New study reveals genetic causes of rare syndrome that manifests as high blood pressure

New study reveals genetic causes of rare syndrome that manifests as high blood pressure

The culmination of two decades of research, a new study reveals the genetic causes of a curious, rare syndrome that manifests as hypertension (high blood pressure) accompanied by short fingers (brachydactyly type E). [More]
Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Individuals with this altered gene have hereditary hypertension (high blood pressure) and at the same time a skeletal malformation called brachydactyly type E, which is characterized by unusually short fingers and toes. The effect on blood pressure is so serious that -- if left untreated -- it most often leads to death before age fifty. [More]
Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases. [More]
Salt may help control infection

Salt may help control infection

Researchers at Vanderbilt University and in Germany have found that sodium - salt - accumulates in the skin and tissue in humans and mice to help control infection. [More]
Not all ARB drugs are equally effective at treating heart failure, reveals NSU researcher

Not all ARB drugs are equally effective at treating heart failure, reveals NSU researcher

Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University researcher's findings. [More]
Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness. [More]
CVRx receives HDE approval for Barostim neo legacy device

CVRx receives HDE approval for Barostim neo legacy device

CVRx, Inc., a privately held medical device company, announced today that it has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration for its Barostim neo legacy device. [More]
CVRx gets CE Mark approval to expand labeling of Barostim neo System as MR Conditional

CVRx gets CE Mark approval to expand labeling of Barostim neo System as MR Conditional

CVRx, Inc., a privately held medical device company, announced today that CE Marking has been granted to expand labeling of the Barostim neo System as MR Conditional, or safe for use in Magnetic Resonance Imaging (MRI) systems under specified conditions. [More]
CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland of the Barostim neo System for the treatment of heart failure. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
Measure Up/Pressure Down campaign improves high blood pressure control in 205,000 patients

Measure Up/Pressure Down campaign improves high blood pressure control in 205,000 patients

Medical groups participating in Measure Up/Pressure Down®, a national hypertension campaign, improved detection or control of high blood pressure for 205,000 Americans living with the disease in the first 12 months of the campaign, the American Medical Group Foundation (AMGF) announced today. [More]
Empagliflozin lowers blood pressure in patients with Type 2 diabetes and hypertension

Empagliflozin lowers blood pressure in patients with Type 2 diabetes and hypertension

An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. [More]
Empagliflozin drug reduces blood pressure in patients with Type 2 diabetes, hypertension

Empagliflozin drug reduces blood pressure in patients with Type 2 diabetes, hypertension

An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago. [More]
New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. [More]
St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014. [More]
Northwestern University awarded NIH grant to conduct phase III Parkinson's neuroprotective study

Northwestern University awarded NIH grant to conduct phase III Parkinson's neuroprotective study

Tanya Simuni, M.D., medical director of Northwestern University's Parkinson's Disease and Movement Disorders Center, was awarded a grant from the National Institutes of Health to conduct a $16 million phase III study of the safety and efficacy of the drug isradipine as a potential neuroprotective agent in Parkinson's disease. [More]
Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. [More]
Heavy exposure to air pollution increases risk for developing hypertension during pregnancy

Heavy exposure to air pollution increases risk for developing hypertension during pregnancy

Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study. [More]
Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative. [More]
CVD expert requests Mexican government to carry out mandatory screening for 18-year-olds

CVD expert requests Mexican government to carry out mandatory screening for 18-year-olds

A cardiovascular disease expert is calling for mandatory screening of 18 year-old Mexicans to halt the CVD epidemic plaguing the nation. Cardiovascular risk factors will be a key theme at the Mexican Congress of Cardiology, held 23 to 27 November in Leon, Guanajuato, Mexico. The Congress is organised by the Mexican Society of Cardiology and features a collaborative programme with the European Society of Cardiology. [More]
Advertisement
Advertisement